Immune-mediated tumor rejection

Ena Wang, Francesco M. Marincola

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Fundamental strides in the understanding of the molecular basis of tumor rejection were made in the last decade thanks to observational studies performed at relevant time points in human cancerous tissues. The following concepts emerged: immune surveillance against tumors is a likely occurrence. When cancer cells evolve to escape the ongoing immune defense, the neoplastic process reaches a clinically observable phase. By necessity, at this stage, escape mechanisms override anti-cancer mechanisms for tumors to be observable. When cancers become established, two molecular phenotypes can usually be observed: one is characterized by a tumor microenvironment infiltrated by immune cells bearing transcriptional signatures consistent with a status of partial activation. Although incapable of dramatically affecting tumor growth, immune infiltration bears a favorable prognostic and/or predictive connotation on the natural history of the disease or its responsiveness to therapy. In this chapter, we will discuss the significance of transcriptional signatures observed in pre-treatment biopsies as predictive of responsiveness to biological therapy. Moreover, we will discuss the transcriptional signatures observable during and after therapy documenting the switch from chronic to acute inflammation that leads to tumor rejection. We will further discuss how chemotherapy and viral oncolytic therapy, both believed to eliminate tumors exclusively through direct cytotoxicity may play an adjuvant role in stimulating this inflammatory switch. Finally, we will discuss how mechanisms leading to tumor rejection, largely overlap those associated with other aspects of immune-mediated tissue-specific destruction (TSD) such as allograft rejection, graft vs. host disease, acute clearance of pathogen and autoimmunity.

Original languageEnglish
Title of host publicationImmunologic Signatures of Rejection
PublisherSpringer New York
Pages281-304
Number of pages24
ISBN (Electronic)9781441972194
ISBN (Print)9781441972187
DOIs
Publication statusPublished - 2011
Externally publishedYes

Fingerprint

Neoplasms
Neoplastic Processes
Biological Therapy
Tumor Microenvironment
Graft Rejection
Acute Disease
Therapeutics
Autoimmunity
Observational Studies
Allografts
Inflammation
Phenotype
Biopsy
Drug Therapy
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wang, E., & Marincola, F. M. (2011). Immune-mediated tumor rejection. In Immunologic Signatures of Rejection (pp. 281-304). Springer New York. https://doi.org/10.1007/978-1-4419-7219-4_18

Immune-mediated tumor rejection. / Wang, Ena; Marincola, Francesco M.

Immunologic Signatures of Rejection. Springer New York, 2011. p. 281-304.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wang, E & Marincola, FM 2011, Immune-mediated tumor rejection. in Immunologic Signatures of Rejection. Springer New York, pp. 281-304. https://doi.org/10.1007/978-1-4419-7219-4_18
Wang E, Marincola FM. Immune-mediated tumor rejection. In Immunologic Signatures of Rejection. Springer New York. 2011. p. 281-304 https://doi.org/10.1007/978-1-4419-7219-4_18
Wang, Ena ; Marincola, Francesco M. / Immune-mediated tumor rejection. Immunologic Signatures of Rejection. Springer New York, 2011. pp. 281-304
@inbook{545b4eff0e1c4df48da4045895b73576,
title = "Immune-mediated tumor rejection",
abstract = "Fundamental strides in the understanding of the molecular basis of tumor rejection were made in the last decade thanks to observational studies performed at relevant time points in human cancerous tissues. The following concepts emerged: immune surveillance against tumors is a likely occurrence. When cancer cells evolve to escape the ongoing immune defense, the neoplastic process reaches a clinically observable phase. By necessity, at this stage, escape mechanisms override anti-cancer mechanisms for tumors to be observable. When cancers become established, two molecular phenotypes can usually be observed: one is characterized by a tumor microenvironment infiltrated by immune cells bearing transcriptional signatures consistent with a status of partial activation. Although incapable of dramatically affecting tumor growth, immune infiltration bears a favorable prognostic and/or predictive connotation on the natural history of the disease or its responsiveness to therapy. In this chapter, we will discuss the significance of transcriptional signatures observed in pre-treatment biopsies as predictive of responsiveness to biological therapy. Moreover, we will discuss the transcriptional signatures observable during and after therapy documenting the switch from chronic to acute inflammation that leads to tumor rejection. We will further discuss how chemotherapy and viral oncolytic therapy, both believed to eliminate tumors exclusively through direct cytotoxicity may play an adjuvant role in stimulating this inflammatory switch. Finally, we will discuss how mechanisms leading to tumor rejection, largely overlap those associated with other aspects of immune-mediated tissue-specific destruction (TSD) such as allograft rejection, graft vs. host disease, acute clearance of pathogen and autoimmunity.",
author = "Ena Wang and Marincola, {Francesco M.}",
year = "2011",
doi = "10.1007/978-1-4419-7219-4_18",
language = "English",
isbn = "9781441972187",
pages = "281--304",
booktitle = "Immunologic Signatures of Rejection",
publisher = "Springer New York",

}

TY - CHAP

T1 - Immune-mediated tumor rejection

AU - Wang, Ena

AU - Marincola, Francesco M.

PY - 2011

Y1 - 2011

N2 - Fundamental strides in the understanding of the molecular basis of tumor rejection were made in the last decade thanks to observational studies performed at relevant time points in human cancerous tissues. The following concepts emerged: immune surveillance against tumors is a likely occurrence. When cancer cells evolve to escape the ongoing immune defense, the neoplastic process reaches a clinically observable phase. By necessity, at this stage, escape mechanisms override anti-cancer mechanisms for tumors to be observable. When cancers become established, two molecular phenotypes can usually be observed: one is characterized by a tumor microenvironment infiltrated by immune cells bearing transcriptional signatures consistent with a status of partial activation. Although incapable of dramatically affecting tumor growth, immune infiltration bears a favorable prognostic and/or predictive connotation on the natural history of the disease or its responsiveness to therapy. In this chapter, we will discuss the significance of transcriptional signatures observed in pre-treatment biopsies as predictive of responsiveness to biological therapy. Moreover, we will discuss the transcriptional signatures observable during and after therapy documenting the switch from chronic to acute inflammation that leads to tumor rejection. We will further discuss how chemotherapy and viral oncolytic therapy, both believed to eliminate tumors exclusively through direct cytotoxicity may play an adjuvant role in stimulating this inflammatory switch. Finally, we will discuss how mechanisms leading to tumor rejection, largely overlap those associated with other aspects of immune-mediated tissue-specific destruction (TSD) such as allograft rejection, graft vs. host disease, acute clearance of pathogen and autoimmunity.

AB - Fundamental strides in the understanding of the molecular basis of tumor rejection were made in the last decade thanks to observational studies performed at relevant time points in human cancerous tissues. The following concepts emerged: immune surveillance against tumors is a likely occurrence. When cancer cells evolve to escape the ongoing immune defense, the neoplastic process reaches a clinically observable phase. By necessity, at this stage, escape mechanisms override anti-cancer mechanisms for tumors to be observable. When cancers become established, two molecular phenotypes can usually be observed: one is characterized by a tumor microenvironment infiltrated by immune cells bearing transcriptional signatures consistent with a status of partial activation. Although incapable of dramatically affecting tumor growth, immune infiltration bears a favorable prognostic and/or predictive connotation on the natural history of the disease or its responsiveness to therapy. In this chapter, we will discuss the significance of transcriptional signatures observed in pre-treatment biopsies as predictive of responsiveness to biological therapy. Moreover, we will discuss the transcriptional signatures observable during and after therapy documenting the switch from chronic to acute inflammation that leads to tumor rejection. We will further discuss how chemotherapy and viral oncolytic therapy, both believed to eliminate tumors exclusively through direct cytotoxicity may play an adjuvant role in stimulating this inflammatory switch. Finally, we will discuss how mechanisms leading to tumor rejection, largely overlap those associated with other aspects of immune-mediated tissue-specific destruction (TSD) such as allograft rejection, graft vs. host disease, acute clearance of pathogen and autoimmunity.

UR - http://www.scopus.com/inward/record.url?scp=80053902600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053902600&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-7219-4_18

DO - 10.1007/978-1-4419-7219-4_18

M3 - Chapter

AN - SCOPUS:80053902600

SN - 9781441972187

SP - 281

EP - 304

BT - Immunologic Signatures of Rejection

PB - Springer New York

ER -